The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Health and Human Services Appropriations Committee PCS for SB 10-A BILL: Committee on Health and Human Services Appropriations and Senator Peaden INTRODUCER: Human Services SUBJECT: January 6, 2009 DATE: REVISED: ANALYST STAFF DIRECTOR ACTION REFERENCE 1. Fabricant **Pre-meeting** Peters HA 2. _____ 3. _____ 4. _____ 5. _____ 6. _____

I. Summary:

This bill reduces the annual appropriation from the General Revenue Fund to the Biomedical Research Trust Fund for the James and Ester King Biomedical Research Program from \$6 million to \$3 million. The bill also reduces the annual appropriation from the General Revenue Fund to the Biomedical Research Trust Fund for the William G. "Bill" Bankhead Jr. and David Coley Cancer Research Program from \$9 million to \$4.5 million.

Funds transferred to the Biomedical Research Trust Fund for the James and Ester King Biomedical Research Program during the 2008-2009 fiscal year in excess of \$3 million must be transferred back to the General Revenue Fund.

Funds transferred to the Biomedical Research Trust Fund for the William G. "Bill" Bankhead Jr. and David Coley Cancer Research Program during the 2008-2009 fiscal year in excess of \$4.5 million must be transferred back to the General Revenue Fund.

This bill substantially amends the following sections of the Florida Statutes: 215.5602 and 381.922.

II. Present Situation:

The James and Ester King Biomedical Research Program was started in the 2004-2005 fiscal year. The purpose of the program is to provide an annual source of funding to support research initiatives related to cancer, cardiovascular disease, stroke, and pulmonary disease. The general revenue appropriation is \$6 million per year, the funds are then transferred to the Biomedical

Research Trust Fund. 85% of the funds appropriated are used to award grants and fellowships. 15% of the funds appropriated are used to administer the program in the Department of Health.

The William G. "Bill" Bankhead Jr. and David Coley Cancer Research Program was started in the 2006-2007 fiscal year. The purpose of the program is to provide research grants to advance progress towards a cure for cancer. The general revenue appropriation is \$9 million per year, the funds are then transferred to the Biomedical Research Trust Fund. 90% of the funds appropriated are used to award grants and fellowships. 10% of the funds appropriated are used to administer the program in the Department of Health.

III. Effect of Proposed Changes:

Section 1 reduces the annual appropriation from the General Revenue Fund to the Biomedical Research Trust Fund for the James and Ester King Biomedical Research Program from \$6 million to \$3 million.

Section 2 reduces the annual appropriation from the General Revenue Fund to the Biomedical Research Trust Fund for the William G. "Bill" Bankhead Jr. and David Coley Cancer Research Program from \$9 million to \$4.5 million.

Section 3 requires that funds transferred to the Biomedical Research Trust Fund for the James and Ester King Biomedical Research Program during the 2008-2009 fiscal year in excess of \$3 million must be transferred back to the General Revenue Fund.

Funds transferred to the Biomedical Research Trust Fund for the William G. "Bill" Bankhead Jr. and David Coley Cancer Research Program during the 2008-2009 fiscal year in excess of \$4.5 million must be transferred back to the General Revenue Fund.

Section 4 provides that the bill shall take effect upon becoming a law.

IV. Constitutional Issues:

A. Municipality/County Mandates Restrictions:

None.

B. Public Records/Open Meetings Issues:

None.

C. Trust Funds Restrictions:

None.

V. Fiscal Impact Statement:

A. Tax/Fee Issues:

None.

B. Private Sector Impact:

The amount of state research grants available for biomedical research will be reduced.

C. Government Sector Impact:

State appropriations for biomedical research will decrease by \$7.5 million annually.

VI. Technical Deficiencies:

None.

VII. Related Issues:

None.

VIII. Additional Information:

A. Committee Substitute – Statement of Substantial Changes: (Summarizing differences between the Committee Substitute and the prior version of the bill.)

None.

B. Amendments:

None.

This Senate Bill Analysis does not reflect the intent or official position of the bill's introducer or the Florida Senate.